Service Hotline +86 400-068-7188

China Respiration System Chemical Medicine Industry Competitive Landscape and Leading Enterprise Research Report, 2013-2017

China Respiration System Chemical Medicine Industry Competitive Landscape and Leading Enterprise Research Report, 2013-2017

China Respiration System Chemical Medicine Industry Competitive Landscape and Leading Enterprise Research Report, 2013-2017

A must-have for enterprise medium to long-term strategic planning

Without deep industry knowledge, it will be difficult to gain any return

English Version:USD7900

Including: Paper back + Electronic Copy + Invoice

Customer Hotline:+86 755 - 82925195 / 82925295

Free Hotline:+86 400-068-7188After-sales Hotline: +86 755-33013088

The Ministry of Commerce of the People's Republic of China designated Qianzhan Industrial Research Institute as the only "regional workstation for dealing with trade friction" in the Guangdong-Hong Kong-Macao Greater Bay Area

Special Statement

We are aware of that the content of our products have been stolen by some ones who changed the design and used it to deceive customers as it is their own products. Customers who are misled may experience no product received or an incomplete product. Therefore, Qianzhan Industrial Research Institute encourage you to arrange an in-person visit to our company before you make the purchase. Qianzhan has the sole copyright of all research reports. We have never had partnership or affiliated with any third party agent. Please recognize the"前瞻"trademark when purchasing reports.To have better investment return or strategic outcomes, you must have a forward-looking vision. Qianzhan Industrial Research Institute - China's leading industry consulting institutions provide you with all the things you need in business!

* The table of contents and the rest of this report are originally created by Qianzhan. Without any prior written permission, it is prohibited to copy or reproduce in any way. To have better investment return or strategic outcomes, you must have a forward-looking vision!

  • Table of Contents

  • Content Summary

China Respiration System Chemical Medicine Industry Competitive Landscape and Leading Enterprise Research Report, 2013-2017

Chapter 1: Development Overview of China Respiratory System Chemical Medicine Industry

1.1 Concept of Respiratory System Chemical Medicine Industry

1.1.1 Definition of Respiratory System Chemical Medicine Industry

1.1.2 Scope Definition of Report on Respiratory System Chemical Medicine Industry

1.1.3 Analysis System for Report on Respiratory System Chemical Medicine Industry

1.2 Features of Respiratory System Chemical Medicine Industry

1.2.1 Development Features of Respiratory System Chemical Medicine Industry

1.2.2 Influencing Factors of Respiratory System Chemical Medicine Industry

1.3 Policy Environment for Respiratory System Chemical Medicine Industry

1.3.1 Introduction and Explanation of Policies Related to Respiratory System Chemical Medicine Industry

1.3.2 Introduction and Explanation of Plans Related to Respiratory System Chemical Medicine Industry

Chapter 2: Development of Respiratory System Chemical Medicine Industry

2.1 Development Overview of Chemical and Pharmaceutical Industry

2.1.1 Development Overview of International Chemical and Pharmaceutical Industry

2.1.2 Development Overview of International Chemical and Pharmaceutical Industry

(1) Operation of Industry

(2) Industry Scale

(3) Competitive Landscape

(4) Trend Outlook

2.2 Development Overview of Respiratory System Chemical Medicine Industry

2.2.1 Concept and Classification of Industry

2.2.2 Operation of Industry

2.2.3 Market Scale of Industry

2.2.4 Development Trend for Industry

(1) Demand Forecast for Respiratory Drugs Industry

(2) Development Trend for Respiratory Drugs Industry

Chapter 3: Analysis of Competition for Nasal Spray Market Segments

3.1 Development Overview of Nasal Spray

3.2 Competition for Major Nasal Sprays

3.3 Nasal Spray Manufacturing Enterprises Compete for Position

3.4 Competition for Major Nasal Sprays in Domestic

3.4.1 Azelastine

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

3.4.2 Mometasone

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

3.4.3 Oxymetazoline

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

3.4.4 Levocabastine

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

3.4.5 Xylometazoline

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

3.5 Competition Trend for Nasal Spray

Chapter 4: Analysis of Competition for Throat Preparation Market Segments

4.1 Development Overview of Throat Preparation

4.2 Competition for Major Throat Preparations

4.3 Throat Preparation Manufacturing Enterprises Compete for Position

4.4 Competition for Major Throat Preparations in Domestic

4.4.1 Dequalinium Chloride

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

4.4.2 Cydiodine

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

4.4.3 Cetrimide/ Benzalkonium Chloride

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

4.4.4 Lidocaine

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

4.5 Competition Trend for Throat Preparation

Chapter 5: Analysis of Competition for Anti-asthmatic Drug Market Segments in Domestic

5.1 Development Overview of Anti-asthmatic Drug

5.2 Competition for Anti-asthmatic Drugs

5.3 Anti-asthmatic Drug Manufacturing Enterprises Compete for Position

5.4 Competition for Major Anti-asthmatic Drugs in Domestic

5.4.1 Budesonide

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

5.4.2 Salmeterol/Fluticasone

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

5.4.3 Doxofylline

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

5.4.4 MonteluKast

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

5.4.5 Compound Methoxyphenamine Hydrochloride

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

5.4.6 Budesonide/Formoterol

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

5.5 Competition Trend for Anti-asthmatic Drug

Chapter 6: Analysis of Competition for Cough and Cold Medicine Market Segments in Domestic

6.1 Development Overview of Cough and Cold Medicine

6.2 Competition for Cough and Cold Medicines

6.3 Cough and Cold Medicine Manufacturing Enterprises Compete for Position

6.4 Competition for Major Cough and Cold Medicines in Domestic

6.4.1 Ambroxol

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

6.4.2 Bromhexine

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

6.4.3 Acetylcysteine

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

6.4.4 Eucalyptol/ Limonene and Pinene

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

6.5 Competition Trend for Cough and Cold Medicine

Chapter 7: Analysis of Competition for Antihistamines Market Segments in Domestic

7.1 Development Overview of Antihistamines

7.2 Competition for Antihistamines

7.3 Antihistamines Manufacturing Enterprises Compete for Position

7.4 Competition for Major Antihistamines in Domestic

7.4.1 Loratadine

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

7.4.2 Cotirizine

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

7.4.3 Desloratadine

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

7.4.4 Mizolastine

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

7.4.5 Levocetirizine

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

7.4.6 Ebastine

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

7.4.7 Epinastine

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

7.5 Competition Trend for Antihistamines

Chapter 8: Analysis of Competition for Other Domestic Respiratory System Medicines Market

8.1 Development Overview of Other Respiratory System Medicines

8.2 Competitive Landscape for Other Major Respiratory System Medicines

8.3 Competitive Position of Other Respiratory System Medicine Manufacturing Corporations

8.4 Competition for Parts of Other Respiratory System Medicines

8.4.1 Pulmonary Surfactant

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

8.4.2 Dermatophagoides Farinae

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

8.4.3 Calf Pulmonary Surfactant

(1) Basic Information

(2) Competition Position for Major Manufacturing Enterprises

(3) Competitive Landscape of Regional Drug Markets

(4) Drug Market Demand Trend

Chapter 9: Analysis of Leading Enterprises in Respiratory System Chemical Medicine Industry

9.1 Overall Situation of Respiratory System Chemical Medicine Manufacturing Enterprises

9.1.1 Comprehensive Overview of Respiratory System Chemical Medicine Manufacturing Enterprises

9.1.2 Sales Ranking of Respiratory System Chemical Medicine Manufacturing Enterprises

9.1.3 Total Profit Ranking of Respiratory System Chemical Medicine Manufacturing Enterprises

9.2 Leading Brands in Respiratory System Chemical Medicine Manufacturing Enterprises and Their Investment Layout in China

9.2.1 Pfizer

(1) Development Profile

(2) Sales Network

(3) Product Structure

(4) Operation Situation

(5) Operation Situation of Pfizer Dalian Plant

1) Profile

2) Production and Marketing Capability

3) Profitability

4) Operation Capability

5) Debt-paying Ability

6) Development Capability

9.2.2 Novartis AG

(1) Development Profile

(2) Sales Network

(3) Product Structure

(4) Operation Situation

(5) Operation Situation of Beijing Novartis Pharma Ltd.

1) Profile

2) Production and Marketing Capability

3) Profitability

4) Operation Capability

5) Debt-paying Ability

6) Development Capability

9.2.3 Merck

(1) Development Profile

(2) Sales Network

(3) Product Structure

(4) Operation Situation

(5) Operation Situation of Hangzhou Moshadong Pharmaceutical Co., Ltd.

1) Profile

2) Production and Marketing Capability

3) Profitability

4) Operation Capability

5) Debt-paying Ability

6) Development Capability

(6) Operation Situation of Shanghai Schering-Plough Co., Ltd.

1) Profile

2) Production and Marketing Capability

3) Profitability

4) Operation Capability

5) Debt-paying Ability

6) Development Capability

9.2.4 Sanofi

(1) Development Profile

(2) Sales Network

(3) Product Structure

(4) Operation Situation

(5) Operation Situation of Shenzhen Sanofi Pasteur Biological Products Co., Ltd.

1) Profile

2) Production and Marketing Capability

3) Profitability

4) Operation Capability

5) Debt-paying Ability

6) Development Capability

9.2.5 Roche Holding Ltd.

(1) Development Profile

(2) Sales Network

(3) Product Structure

(4) Operation Situation

(5) Operation Situation of Shanghai Roche Pharmaceutical Ltd.

1) Profile

2) Production and Marketing Capability

3) Profitability

4) Operation Capability

5) Debt-paying Ability

6) Development Capability

9.2.6 Glaxo Smith Kline

(1) Development Profile

(2) Sales Network

(3) Product Structure

(4) Operation Situation

(5) Operation Situation of Shanghai Glaxosmithkline Biological Products Co., Ltd.

1) Profile

2) Production and Marketing Capability

3) Profitability

4) Operation Capability

5) Debt-paying Ability

6) Development Capability

9.2.7 AstraZeneca

(1) Development Profile

(2) Sales Network

(3) Product Structure

(4) Operation Situation

(5) Operation Situation of Jiangsu AstraZeneca Co., Ltd.

1) Profile

2) Production and Marketing Capability

3) Profitability

4) Operation Capability

5) Debt-paying Ability

6) Development Capability

9.2.8 Johnson & Johnson

(1) Development Profile

(2) Sales Network

(3) Product Structure

(4) Operation Situation

(5) Operation Situation of Xian Janssen Pharmaceutical Ltd.

1) Profile

2) Production and Marketing Capability

3) Profitability

4) Operation Capability

5) Debt-paying Ability

6) Development Capability

9.2.9 Eli Lilly

(1) Development Profile

(2) Sales Network

(3) Product Structure

(4) Operation Situation

(5) Operation Situation of Eli Lilly and Company

1) Profile

2) Production and Marketing Capability

3) Profitability

4) Operation Capability

5) Debt-paying Ability

6) Development Capability

9.2.10 Boehringer Ingelheim

(1) Development Profile

(2) Sales Network

(3) Product Structure

(4) Operation Situation

(5) Operation Situation of Boehringer Ingelheim Shanghai Pharmaceuticals Co., Ltd.

1) Profile

2) Production and Marketing Capability

3) Profitability

4) Operation Capability

5) Debt-paying Ability

6) Development Capability

9.3 Case Study of Leading Enterprises of Domestic Respiratory System Chemical Medicine Industry

9.3.1 Shenzhen Daphne Pharmaceuticals Co., Ltd.

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

9.3.2 Changzhou Jinyuan Pharmaceutical Co., Ltd.

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

9.3.3 China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

9.3.4 Beijing Wellso Pharmaceutical Co., Ltd.

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

9.3.5 Heilongjiang Fuhe Huaxing Pharmaceutical Co., Ltd.

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

9.3.6 Reyoung Pharmaceutical Co., Ltd.

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

9.3.7 Southwest Pharmaceutical Co., Ltd.

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

9.3.8 Beijing Jiuhe Pharmaceutical Co., Ltd.

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

9.3.9 Jiangxi Kelun Pharmaceutical Co., Ltd.

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

9.3.10 Tianjin Pharmaceutical Research Institute Co., Ltd.

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

9.3.11 Beijing Laneva Pharmaceutical Co., Ltd.

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

9.3.12 ChongQing Carelife Pharmaceutical Co., Ltd.

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

9.3.13 Jiangsu Lianhuan Pharmaceutical Co., Ltd.

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

9.3.14 Hunan Jiudian Pharmaceutical Co., Ltd.

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

9.3.15 Guizhou Yunfeng Pharmaceutical Co., Ltd.

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

9.3.16 Shenzhen Haibin Pharmaceutical Co., Ltd.

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

9.3.17 Biochemical Pharmaceutical Factory of Zhuhai S.E.Z

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

9.3.18 Changzhou Siyao Pharmaceuticals Co., Ltd.

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

9.3.19 Chongqing Huapont Pharm. Co., Ltd.

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

9.3.20 Yangtze River Pharmaceutical Group

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

9.3.21 Hainan Poly Pharm Co., Ltd.

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

9.3.22 Beijing Double-Crane Pharmaceutical Co., Ltd.

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

9.3.23 Jiangsu Nhwa Pharmaceutical Co., Ltd.

(1) Development Overview

(2) Product and Market Positioning

(3) Situation of Market Distribution

(4) Profile of Major Respiration System Drugs

(5) Overall Operation

1) Production and Marketing Capability

2) Profitability

3) Operation Capability

4) Debt-paying Ability

5) Development Capability

(6) Operational Advantages and Disadvantages

(7) Investment, M&A and Restructuring

(8) Latest Development Trend

Reporting core values

Respiratory system disease is kind of common and frequently-occurring disease. Data shows China’s respiratory system disease (excluding lung cancer) ranks as the fourth death cause in urban areas (13%) and ranks as the third one (16.4%) in rural areas. On account of absorption of physical and chemical factor due to air pollution, smoking, and development of industrial economy, and the aging of population, the morbidity of respiration system disease in China rises prominently. So, the huge demand for respiration system drugs show a bright prospect for the industry.

Main Contents of report

Respiratory system disease is kind of common and frequently-occurring disease. Data shows China’s respiratory system disease (excluding lung cancer) ranks as the fourth death cause in urban areas (13%) and ranks as the third one (16.4%) in rural areas. On account of absorption of physical and chemical factor due to air pollution, smoking, and development of industrial economy, and the aging of population, the morbidity of respiration system disease in China rises prominently. So, the huge demand for respiration system drugs show a bright prospect for the industry.

With the growing competition in respiration system chemical medicine industry, acquisition and capital operation among large enterprises become more and more frequent. The domestic excellent enterprises in the industry pay more attention to the industry market research, especially to the in-depth researches on the industry development environment and customer demand trend changes. Because of this, a large number of excellent respiration system chemical medicine enterprises rise up rapidly, and gradually become leading corporations in respiration system chemical medicine industry!

With Forward’s long-term tracking and collecting market data of respiration system chemical medicine industry, we roundly and accurately analyze the industry structure system for you from the view of mastering the whole industry. This report mainly analyzes the industry from the aspects of all market segments in respiration system chemical medicine industry, which details the development overview of market segments of all kinds of respiration system chemical medicines associated with nasal sprays, throat medicines, anti-asthmatic agents, and cold medicines, the competitive landscape of medicines, the competition for corporate position and competitive landscape of regional market; and introduces the competition situation for major products among all kinds of medicines, the urban competitive landscape as well as the market demand trend. Corporations can clearly address a series of related-problems. Such as who are major competitive rivals? Who are its potential rivals for the kind of product? What is the product positioning for competitive rivals and where are the regional markets?

The report will help you to deeply master the competition situation of industry, and moves that competitors make, and also help you to clearly learn the strengths and weakness of yourselves, as well as the gap between you and those excellent enterprises. Referring to strategies and practices in foreign and domestic leading enterprises, you can adjust your competitive strategies and your pace timely, enhance your sense of urgency and improve your competitiveness.

Here, we would like to express our sincere gratitude to China Association of Pharmaceutical Commerce (CAPC), Ministry of State Information Center, Bureau of Statistics of China, International Information Research Institute, Chinese Academy of International Trade and Economic Cooperation, Tsinghua University Library, Development Research Center of the State Council and Beijing Essence Forward Research Center, for their great support when we conduct this report!

Notice: All the market data, especially corporations' ranking data in the report, only for business reference. Please do not take the data for enterprise publicity. Thank you! Or Forward shall not take any responsibility for any consequences!

Special tips: Ignoring some subtle hints in the violent change of external environment, and failure of updating strategic decisions timely will finally lead to the loss of competitive advantage. A true successful company will make scientific researches on external environment consciously or unconsciously, so as to formulate a key scientific operating strategy!

Best wishes for every enterprise with a big dream that can draw up a high-quality operating decision, to effectively avoid the risks and continuously gain the success.

Qianzhan Business Information Co., Ltd. Industry Research Center
Research Team of Respiratory System Chemical Medicine Industry

For any special needs, please contact us.Customize Your Report

  • The National Bureau of Statistics Foreign-related investigation Permission

  • National Innovation Company and Dual Software Certified Enterprise

  • The only DRC desginated Enterprise of the Industry Yearbook

  • National Ministry of Commerce designated Industrial Early Warning and Monitoring Workstation

  • Guangdong Province Enterprise of Observing Contract and Valuing Credit

Qianzhan Industrial Research Institute· The leading company of China Business Consulting

  • 01

    Qianzhan is an industry consulting service provider with national innovation company qualification, independent research and development of industrial big data and Dual Software Certification.

  • 02

    Qianzhan is a consulting and research organization that has been engaged in business consulting for over 16 years in China.

  • 03

    Qianzhan is a consulting service provider with a team of nearly 300 industrial researchers and analysts.

  • 04

    Qianzhan is a consulting service provider with an in-house expert pool of 1200 experts.

  • 05

    Qianzhan is a research and consulting organization that have served 180000 clients and received over positive comments from 100000 of our clients.

  • 06

    Qianzhan is an industry research and consulting organization that has been designated by the highest authority, the DRC, to prepare the yearbook.

  • 07

    Qianzhan is an industry planning and consulting organization that adopts the internationally synchronized SCP scientific analysis model and the perfect industry chain research map to guide the business planning and consulting.

  • 08

    Qizhan is a consulting service organization that helps enterprises to solve the five aspects of industry research, planning, strategic design, capital operation and implementation.

What Else do We Offer

Contact Us

Shenzhen Headquarter

Free Hotline:+86 400-068-7188

Customer Hotline:+86 755 - 82925195 / 82925295

Email Address:service@qianzhan.com

3rd Floor, FIYTA Building West, High Tech South Avenue 1, Nanshan District, Shenzhen, China

Shanghai Office

Location:Rm.1106, Building 1, Jiayu International Plaza, Songhu Road, Yangpu District,
Shanghai, China